JMP Securities analyst Aaron Hecht downgrades Innovative Ind Props (NYSE:IIPR) from Market Outperform to Market Perform.
Accuray’s Precision Treatment System Gains Approval in China, Expanding Cancer Care Options
Accuray Incorporated (NASDAQ:ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical
